Global Financial Private Client’s Royalty Pharma RPRX Stock Holding History

Global Financial Private Client’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-115	Closed	-$3.08K	–	703
2023 Q3	$3.08K	Hold	115	–	–	﹤0.01%	541
2023 Q2	$3.53K	Hold	115	–	–	﹤0.01%	526
2023 Q1	$4.13K	Hold	115	–	–	﹤0.01%	521
2022 Q4	$4.54K	Hold	115	–	–	﹤0.01%	496
2022 Q3	$4.62K	Hold	115	–	–	﹤0.01%	477
2022 Q2	$4.92K	Hold	115	–	–	﹤0.01%	458
2022 Q1	$4.53K	Hold	115	–	–	﹤0.01%	475
2021 Q4	$4.58K	Hold	115	–	–	﹤0.01%	460
2021 Q3	$4.17K	Hold	115	–	–	﹤0.01%	407
2021 Q2	$4.86K	Hold	115	–	–	﹤0.01%	411
2021 Q1	$4.95K	Hold	115	–	–	﹤0.01%	364
2020 Q4	$5.76K	Hold	115	–	–	﹤0.01%	343
2020 Q3	$4.9K	Hold	115	–	–	﹤0.01%	344
2020 Q2	$5.34K	Buy	+115	New	+$5.69K	﹤0.01%	386

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Global Financial Private Client's RPRX Position: Q4 2023 in Review

Global Financial Private Client sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 115 shares — an estimated $3.08K sold.

Global Financial Private Client first reported a position in RPRX in Q2 2020 and held it in 14 quarters. The position peaked at $5.76K in Q4 2020. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Global Financial Private Client reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Global Financial Private Client sold 115 Royalty Pharma shares in Q4 2023, an estimated $3.08K.
Global Financial Private Client first reported a position in Royalty Pharma in Q2 2020 and held it in 14 quarters.
Global Financial Private Client's Royalty Pharma position peaked at $5.76K in Q4 2020.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Global Financial Private Client's 13F filing for Q4 2023, filed 16 May 2024.